Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tetrahydrouridine (NSC-112907; THU) 是一种多药耐药调节剂。它可用于癌症治疗,使肿瘤细胞对放射治疗更加敏感。 它是一种竞争性胞苷脱氨酶 (CDA) 抑制剂,可抑制 ara-C 和吉西他滨等细胞毒性脱氧胞苷类似物分解代谢中的脱氨作用。
产品描述 | Tetrahydrouridine (NSC-112907; THU) is a multidrug resistance modulator. It can be used in cancer treatment to make tumor cells more sensitive to radiation therapy. THU is a competitive cytidine deaminase(CDA) inhibitor that inhibits deamination in the catabolism of cytotoxic deoxycytidine analogs such as ara-C and Gemcitabine. |
体外活性 | To test how Tetrahydrouridine affects the Gemcitabine-mediated anti-neoplastic effect on pancreatic and lung carcinoma cells, a combination therapy is performed. As expected, high CDA expression in BxPC-3 and H441 results in improved Gemcitabine sensitivity after a 100 μM Tetrahydrouridine treatment. The sensitivity of BxPC-3 and H441 cell lines increases by as much as approximately 2.1 and 4.4 fold respectively. On the other hand, MIAPaCa-2 and H1299 cells unexpectedly become more sensitive to Gemcitabine with low CDA expression. MIAPaCa-2 and H1299 cells show a change in an IC50?of 2.2 and 2.3 fold respectively. However, Panc-1 and H322 cells do not show significant changes in drug sensitivity. These data suggested that Tetrahydrouridine can sensitize some pancreatic and lung carcinoma cells to Gemcitabine-induced cell death regardless of CDA expression levels. Tetrahydrouridine inhibits S-phase without apoptosis. |
体内活性 | Tetrahydrouridine (167 mg/kg) followed by DAC (1.0 mg/kg) results in death in one male and eight females. Animals surviving to scheduled termination are generally asymptomatic with no treatment related effects observed in body weights, food consumption, clinical chemistry and urinalysis for a treatment up to 1.0 mg/kg DAC in combination with 167 mg/kg Tetrahydrouridine in animals. |
别名 | NSC 112907, NSC112907, 四氢尿苷, NSC-112907 |
分子量 | 248.23 |
分子式 | C9H16N2O6 |
CAS No. | 18771-50-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10mg/mL (40.29mM)
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.0285 mL | 20.1426 mL | 40.2852 mL | 100.713 mL |
5 mM | 0.8057 mL | 4.0285 mL | 8.057 mL | 20.1426 mL | |
10 mM | 0.4029 mL | 2.0143 mL | 4.0285 mL | 10.0713 mL | |
20 mM | 0.2014 mL | 1.0071 mL | 2.0143 mL | 5.0357 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tetrahydrouridine 18771-50-1 Chromatin/Epigenetic DNA Methyltransferase NSC 112907 NSC112907 四氢尿苷 NSC-112907 Inhibitor inhibitor inhibit